A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Phase 2 Terminated 54 enrolled Assembly Biosciences

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha (Peg-IFNα) in Chinese participants with chronic hepatitis B virus infection (cHBV)

Timeline

Start: 2021-02-18
Primary completion: 2022-12-02
Completion: 2022-12-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Peginterferon alfa-2a	Protein / enzyme biologic	180 ug	Subcutaneous
Subject	Vebicorvir	Small molecule	300 mg	Oral
Background	ETV	Unknown	0.5 mg	Oral

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Summary

Timeline

Drugs

Indications